TG Therapeutics Financial Ratios
NASDAQ: TGTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
TG Therapeutics ratio analysis
TG Therapeutics earned a net margin of 72.6% in FY 2025, up from 7.1% a year earlier. Gross margin was 83.7% compared with a median of 89.4% over the prior 4 years. Return on equity reached 69.0%, meaning TG Therapeutics generated 0.69 dollars of profit for every dollar of shareholders' equity, an unusually high figure that often reflects a small equity base after share buybacks.
Debt-to-equity stood at 0.38 versus 1.10 the year before, and the current ratio was 4.10. At the end of FY 2025, TGTX traded at 10.6 times earnings; across the 3 fiscal years shown, its year-end P/E ranged from 10.6 to 200.3, with a median of 189.8. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
TG Therapeutics financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E ratio (at fiscal year end) | 10.57 | 200.33 | 189.78 | — | — | — | — | — | — | — |
| Price / sales | 6.86 | 13.27 | 10.38 | 575.19 | 375.58 | 39,471.44 | 6,296.28 | 2,288.83 | 3,348.49 | 1,500.28 |
| Price / book | 6.52 | 19.64 | 15.11 | 27.34 | 10.59 | 11.55 | 24.78 | 14.47 | 7.60 | 6.36 |
| Gross margin | 83.7% | 88.3% | 94.0% | 90.5% | 88.2% | — | — | — | — | — |
| Operating margin | 20.0% | 12.7% | 8.8% | -7,839.0% | -5,154.3% | -179,996.1% | -111,220.4% | -114,736.8% | -78,100.0% | -51,953.3% |
| Net margin | 72.6% | 7.1% | 5.4% | -8,036.3% | -5,204.1% | -183,803.3% | -113,730.9% | -114,132.9% | -77,944.7% | -51,482.2% |
| Free cash flow margin | -4.1% | -12.3% | -13.4% | -6,326.2% | -4,425.7% | -141,357.9% | -87,458.6% | -84,878.3% | -61,685.5% | -40,744.1% |
| Return on equity (ROE) | 69.0% | 10.5% | 7.9% | -382.0% | -146.8% | -53.8% | -447.7% | -721.8% | -176.8% | -218.2% |
| Return on assets (ROA) | 42.1% | 4.0% | 3.8% | -115.6% | -91.7% | -44.7% | -106.0% | -207.5% | -121.7% | -142.8% |
| Debt / equity | 0.38 | 1.10 | 0.62 | 1.21 | 0.29 | 0.06 | 0.75 | 0.00 | 0.00 | 0.00 |
| Current ratio | 4.10 | 6.25 | 5.92 | 3.16 | 5.06 | 6.99 | 1.77 | 2.03 | 3.34 | 3.01 |
| Revenue growth | 87.3% | 40.8% | 8,290.0% | -58.4% | 4,300.7% | 0.0% | 0.0% | 0.0% | 0.0% | — |
| EPS growth | 1,746.7% | 66.7% | — | — | — | — | — | — | — | — |